Q: What’s next beyond the current ClearikonFLEX™ bandage?
A: Our smart trauma bandage, ClearikonSYNC™ is in development—continuously monitoring wounds, storing data offline, and communicating status to medics. This positions Clearikon™ for leadership in precision wound care and digital health integration.
Q: What does ClearikonSYNC™ S M A R T™ Bandage mean?
A: Answer:
Scalable: Designed for efficient manufacturing and deployment across diverse care environments - from battlefield triage to civilian hospitals - supporting broad adoption and cost-effective distribution.
Modular: Offers customizable configurations tailored to wound type, severity, and care setting, minimizing inventory complexity and maximizing clinical versatility.
Adaptive: Continuously monitors wound conditions (e.g., exudate levels, temperature shifts, infection markers) using intelligent sensing and feedback to guide care decisions.
Responsive: Tracks and communicates the status of interventions - such as moisture control, thermal modulation, or antimicrobial engagement - based on real-time wound data.
Targeted: Enables precision wound management by aligning sensor insights with specific therapeutic actions, optimizing healing trajectories and resource utilization.
Q: Why should Veterans invest in Clearikon™?
A: You know firsthand the challenges of combat casualty care. ClearikonFLEX™ directly addresses those pain points—reducing unnecessary bandage changes, lowering infection risk, and multiplying caregiver capacity. Your investment helps bring battlefield-ready innovation to the people who need it most.
⚔️ Battlefield Readiness
Q: Will this technology truly hold up in combat conditions?
A: Yes. ClearikonFLEX™ is engineered for rugged environments—resistant to dirt, sweat, water, and extreme temperatures. It’s designed with the realities of combat in mind, not just hospital settings.
🎖️ Differentiation & Advantage
Q: How is this different from what medics already carry?
A: Unlike opaque trauma dressings, ClearikonFLEX™ enables continuous wound visibility and monitoring. This means fewer dressing changes, faster triage, and better outcomes—an advantage that veterans understand translates to saved lives and reduced costs.
Q: How does investing make a difference for service members?
A: Your investment accelerates deployment of technology that directly supports wounded warriors in austere environments. It’s not just financial return—it’s mission-driven impact that veterans can be proud to back.
Q: What’s the market potential for investors?
A: Clearikon™ is targeting four high-value markets—Military, Hospital, Home Health, and Veterinary—together worth over $16B globally. Military adoption alone represents a $5.77B opportunity by 2025. Early revenue is expected in 2026, with scalable manufacturing already in place.
Q: How do you overcome regulatory hurdles?
Q: How do you overcome regulatory hurdles?
A: ClearikonFLEX™ is a Class I medical device—low risk, non-invasive, with a 2-day FDA notification pathway. No 510(k) required. Our advisors also anticipate a unique CPT code, enabling direct billing and strong reimbursement potential.
Q: What are the FDA clearance pathways?
A: 510(k) Process (Class II & some Class I devices):
Companies demonstrate their device is “substantially equivalent” to a legally marketed predicate device.
Submission includes technical data, performance testing, and sometimes limited clinical evidence.
FDA review typically takes months, offering a faster, lower‑cost route compared to full Premarket Approval (PMA).
Outcome: FDA issues a clearance letter, allowing U.S. commercialization.
Class I Devices – Notification/Exemption:
Many low‑risk Class I devices (e.g., bandages, stethoscopes, tongue depressors) are exempt from 510(k) requirements.
Instead, manufacturers must register their establishment and list their devices with the FDA.
No formal clearance letter is issued; compliance focuses on general controls such as proper labeling, good manufacturing practices, and adverse event reporting.
For investors, this means minimal regulatory burden and rapid market entry, though companies must still maintain FDA compliance infrastructure.
Q: What are CPT and HCPCS codes?
Q: What are CPT codes
A: CPT (Current Procedural Terminology) codes are five-digit numeric codes developed and maintained by the American Medical Association (AMA) to describe medical, surgical, and diagnostic services performed by healthcare professionals. They are used universally for billing purposes by healthcare providers, government payers, and private insurers. CPT codes are divided into three categories: Category I for standard procedures, Category II for performance measurement, and Category III for emerging technologies
Q:What are HCPCS codes?
A:HCPCS (Healthcare Common Procedure Coding System) codes are alphanumeric and are used to report medical procedures and services to Medicare, Medicaid, and other health insurance programs. HCPCS includes two primary levels: Level I, which is identical to CPT codes (also known as CPT-4), and Level II, which covers products, supplies, and services not included in CPT codes, such as durable medical equipment, ambulance services, and certain drugs.
Level II codes are maintained by the Centers for Medicare and Medicaid Services (CMS) and are in the public domain, unlike CPT codes, which are copyrighted by the AMA. The key difference lies in their scope, with CPT focusing on procedures and HCPCS, particularly Level II, covering non-physician services and supplies.
Q: Is there evidence this ClearikonSYNC™ reduces infection risk?
Q: Is there evidence this reduces infection risk?
A: Clinical advisors and early trials confirm fewer dressing changes correlate with lower infection rates. We are expanding validation with military and hospital partners to strengthen adoption.
The hospital wound care market is a substantial and steadily growing segment, driven by the rising prevalence of chronic wounds, an aging population, and increasing rates of diabetes and obesity. In the United States, the hospital segment accounted for approximately 29.5% of the global chronic wound care market, which was valued at $18.6 billion in 2025, translating to an estimated $5.49 billion for hospital-based wound care. By 2035, this is projected to reach $7.88 billion, reflecting a CAGR of 3.7%.
The global home healthcare market for wound care is valued at $3.5 billion in 2025, projected to reach $4.8 billion by 2035 (CAGR 3.1%). In the US, chronic wounds affect approximately 6.5 million people annually, with home health agencies playing a critical role in managing these patients.
The global combat casualty care (combat dressing) market is valued at $5.77 billion in 2025, projected to reach $7.17 billion by 2035 (CAGR 2.2%). The US Department of Defense (DoD) is the primary buyer, with significant procurement budgets for trauma care R&D, battlefield wound care, and smart medical devices.
The global veterinary bandage (animal wound care) market is valued at $1.47 billion in 2025, projected to reach $2.10 billion by 2030 (CAGR 7.4%). The US market is estimated at $316.2 million in 2024, growing to $466 million by 2030 (CAGR 6.8%).
Hospital Savings Analysis
*Per the American Hospital Association (AHA), there are 6,093 hospitals in the U.S. totaling 913,136 staffed beds. This averages to about 150 beds per hospital treating about 5,655 unique patients per month. Of these about 1,500 to 2,000 need bandaging. We forecast a conservative yet steady adoption rate from 2026- 2030.
Regulatory Analysis
About MRC Global: Delivers comprehensive solutions for regulatory, quality, clinical, transactional and physician leadership/key opinion leader (KOL) advisory services to the life sciences community - medical device, pharmaceutical, biological and tissue companies.
Specific professional services include: global regulatory assessment, planning and strategy; pre-submission, 510(k), Investigational Device Exemption (IDE), Pre-Market Approval (PMA), de novo preparation and submission to FDA; European technical file and design dossier preparation; FDA, Notified Body, and ISO 13485 audit preparation and participation; Tissues auditing, licensing and registration; supplier and internal audits, valuation services (company or device), royalty arrangements, co-branding FMV and innovative processes to document KOL status and payment rate sheet development, to name a few.
Reimbursement Analysis
About RRS: After a career working reimbursement issues with Amersham (now GEHC) Ms. Ossias founded RRS in 2005. RRS Canada opened in 2010.
RRS supports various clients including Accuray, Alliance Health, Aspect Imaging, Aurora Imaging Technologies, Bayer Healthcare Pharmaceuticals, Biogen, Bio Marin, Bracco, CMC Contrast AB, Cambridge Heart, Covidien, Digirad, Esaote, EUSA Pharma, Fuji Medical, GammaMedica, Guerbet, Jazz Pharmaceuticals, Lundbeck, Merck, NeoProbe, Nuubo, Oxford Pharmascience UK, PETNET, Philips, Planmed OY, Quest Medical, RepliGen, Siemens, Slate Pharma, Sprout Pharma,Terason, Tesaro Bio, TEVA, United Pharmacy Partners, Zevacor.
They have affiliates in the European Union and United Kingdom to assist entering and being successful in those markets.
- Unique Access & Reduced Disruption: Peelable transparent flap allows frequent inspection/treatment without full bandage removal, minimizing pain, stress, and skin trauma.
- Long-Term Efficiency: Potential for significant time and cost savings by reducing full bandage changes, treatment times and accelerating healing.
-Nuanced Exudate Management: The Bandage is dressing agnostic allowing optimal dressings and drains to be installed and changed as often as needed without a complete bandage change.
-Continuous Visual Monitoring: Transparent flap enables instant wound observation, aiding timely intervention.
- Potential for Enhanced Compliance: Less pain and less frequent changes may improve patient adherence.
- High Initial Cost: The more expensive advanced unit cost compared to common or new versions of traditional dressings (e.g., films, basic foams).
- Limited Brand Recognition: Early entrant in the human wound care market compared to major competitors.
- Application Learning Curve: Unique design may require some limited user education for optimal use.
- Market Acceptance - Initial resistance to change in nursing and patient care.
- Massive Human Wound Care Market: Significant potential for chronic wounds (diabetic, pressure, venous ulcers) where its core benefits are highly valuable.
- Strategic Partnerships: Collaborations with major healthcare distributors, Group Purchasing Organizations (GPO), and wound care specialists.
- Product Line Expansion: Development of diverse sizes, absorbency levels, integrated features (e.g., antimicrobials)and sensors to monitor wounds via apps.
- Value-Based Marketing: Emphasize long-term cost-effectiveness, reduced nursing time, and improved patient outcomes to justify initial price.
- Telemedicine Synergy: Transparency supports remote wound assessment.
- Dual Market Opportunity: Products are positioned to offer solutions to address needs for both the Human Health and Animal Health.
- Cost Sensitivity: High initial price may be a significant barrier in a price-conscious healthcare market, especially against much cheaper alternatives (e.g., gauze, basic films).
- Competitor Innovation: Existing large players may develop similar "access" features or introduce other disruptive technologies (e.g., advanced smart dressings).
- Regulatory Hurdles: Rigorous and costly FDA approval processes for human use.
- Entrenched Brand Loyalty: Major brands have deep roots and established trust with clinicians and procurement.
- Disruptive Topical Treatments: Highly effective topical solutions that reduce the need for complex dressings.